🇺🇸 FDA

Company profile · Sponsor

GALECTIN

GALECTIN THERAPEUTICS INC

GALT · NYSE pharma NORCROSS, GA, USA
Pipeline
12
Drugs
0
Patents
8

Quick answer

GALECTIN (GALT) is a pharma company. headquartered in NORCROSS, GA, USA. listed on NYSE. NovaPharmaNews links 12 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker GALT
Exchange NYSE
Company type pharma
Headquarters NORCROSS, GA, USA
SEC CIK 0001133416

Pipeline (12)

Search pipeline →

  1. Placebo of BELAPECTIN, BELAPECTIN

    GALECTIN

    Esophageal Varices in NASH Cirrhosis

    phase 3 small molecule active

    1 trial

  2. belapectin

    GALECTIN

    Prevention of Esophageal Varices

    phase 3 small molecule terminated

    1 trial

  3. GM-CT-01

    GALECTIN

    Cancer of the Bile Duct

    phase 2 small molecule terminated

    1 trial

  4. GM-CT-01

    GALECTIN

    Colorectal Cancer

    phase 2 small molecule terminated

    2 trials

  5. GM-CT-01 plus 5-Fluorouracil

    GALECTIN

    Colorectal Cancer

    phase 2 small molecule terminated

    1 trial

  6. GR-MD-02

    GALECTIN

    Nonalcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  7. GR-MD-02

    GALECTIN

    Hypertension, Portal

    phase 2 small molecule completed

    1 trial

  8. GR-MD-02

    GALECTIN

    Psoriasis

    phase 2 small molecule completed

    1 trial

  9. 1 mg/kg GR-MD-02

    GALECTIN

    Metastatic Melanoma

    phase 1 mab completed

    1 trial

  10. GR-MD-02

    GALECTIN

    Melanoma

    phase 1 small molecule completed

    1 trial

  11. GR-MD-02

    GALECTIN

    Non-Alcoholic Steatohepatitis (NASH)

    phase 1 small molecule completed

    1 trial

  12. belapectin

    GALECTIN

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

Patents (8)

Search patents →

  1. US 12377102

    Compounds for the prevention and treatment of medical disorders and uses thereof

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11583530

    Compounds for the prevention and treatment of medical disorders and uses thereof

    Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11576924

    Compounds for the prevention and treatment of diseases and the use thereof

    Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11413303

    Methods for treatment of arthritis

    Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10799525

    Composition of novel carbohydrate drug for treatment of human diseases

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10744154

    Galactose-pronged polysaccharides in a formulation for antifibrotic therapies

    Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10420793

    Composition of novel carbohydrate drug for treatment of human diseases

    Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9974802

    Composition of novel carbohydrate drug for treatment of human diseases

    Expires Mon May 17 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is GALECTIN?

GALECTIN (GALT) is a pharma company. headquartered in NORCROSS, GA, USA. listed on NYSE. NovaPharmaNews links 12 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does GALECTIN sponsor?

We track 12 ClinicalTrials.gov-linked programs for GALECTIN, including Placebo of BELAPECTIN, BELAPECTIN and 11 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does GALECTIN company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.